Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...

Commenting on the new labeling, Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals, said, “By expanding Qelbree’s label to include new data on the pharmacodynamics and ...

A release from the CMO on Friday night said Reddy urged Union Minister for Housing and Urban Development Manohar Lal Khattar to allocate one lakh solar pumps under PM Kusum to ensure continuous supply ...

In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...

Meanwhile, Supernus CEO Jack A. Khattar highlighted the company's commitment to evidence-based ADHD treatment options. The label update does not change Qelbree's indication or safety information. It ...